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ABSTRACT _
There is only one well-estahlished relationship hetween
blood cholesterol lipid fractions and coronary artery
disease (CAO) that meets all the Heiss and Tyroler cri-
teria of causality. While there are a numher of blood
lipid fractions, only 1.01. cholesterol satisfies these cri-
teria. We review the effect of reducing low density lipo-
protein (1.01.) cholesterol levels on CAD in the land-
mark lipid intervention trials performed since 1972.
Lowering of LOL cholesterol consistently and systemat-
ically resulted in a reduction of cardiovascular events,
Introduction
Greater than 200 risk factors have been linked to
coronary artery disease (CAD). However, to estab-
lish that a risk factor is causative, a number of crite-
ria must be satisfied. Heiss and Tyroler 111 first
published guidelines for establishing causality be-
tween a risk factor and a disease that many epide-
miologists have reinforced for over 20 years. These
original seven criteria are shown in Table 1 and are
further strengthened by two additional criteria.
One needs to assess the strength and independence
of association, biological consistency, observational
consistency across many studies, and the ability to
reliably measure the risk factor of interest (Table
1). For example, oxidation of low density lipopro-
tein (LDL) cholesterol might be difficult to assess as
a risk factor because a valid method of measure-
ment is not available to link in vivo and in vitro
models. A temporal relationship between a risk
factor and a disease should also be observed. In
addition to these criteria developed by Tyroler, two
other criteria should be established: (1) evidence
from animal models in which a risk factor can be
altered to produce or reduce disease; and (2) evi-
dence from genetic human models where the risk
factor is exaggerated, resulting in a severe and pre-
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irrespective of the therapy applied or the changes in
high density lipoprotein (HOL) cholesterol or triglycer-
ide levels. Findings accumulated over many studies and
many years provided sufficient evidence to satisfy all
the criteria required to estahlish a causative relationship
between LOL cholesterol and CAO. Consistent inter-
venrional benefit demonstrated that reduction of LOL
cholesterol is currently the treatment of choice in pre-
vention of heart disease.
mature form of the disease. Finally, before widely
recommending a therapy in relation to the identi-
fied risk factor, the interventional benefit should be
assessed. There is a well-established cross-sectional
epidemiological relationship between blood choles-
terol levels and coronary artery disease (CAD).
Most coronary disease in the United States occurs
with levels of cholesterol below 240 mg/dL. In a
study performed in China a few years ago [2], al-
though absolute risk was fairly low, a relationship
between relative risk of CAD and cholesterol in
quartiles of 120, 150, 170, and 200 mg/dL was ob-
served over the whole range of cholesterol levels. At
any given cholesterol level, the risk of CAD is aug-
mented if other risk factors such as smoking, hyper-
tension, diabetes, and previous coronary disease are
involved. Combinations of risk factors in the same
individual increase the risk of CAD substantially.
The risk of further CAD for a subject with high
LDL cholesterol levels (> 160 mg/dL) and who had
previous coronary disease is 10 times that of an in-
dividual whose LDL cholesterol level is lower than
130 mg/dL. Based on findings related to these risk
factors, and supported by information available on
genetic disorders, pathophysiology, and epidemio-
logical evidence, current National Cholesterol Edu-
cation Program (NCEP) guidelines [31 recommend
that LDL cholesterol levels and other risk factors be
used to identify individuals likely to develop CAD;
changes in LDL cholesterol should also be used to
guide the effectiveness of cholesterol-lowering ther-
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Table I Criteria for assessing risk factor IHD relationship
Strength of association
Independence of association
Biological consistency
Observational consistency
Measurement validity
Temporal relationship
Animal models
Genetic human models
Interventional benefit
IHD, ischemic heart disease.
apy. In this paper, we review the outcomes of a
number of cholesterol-lowering interventions to
identify whether LOL cholesterol is the most benefi-
cially altered causative factor for reducing cardio-
vascular events.
Cholesterol-Lowering Interventions
A high LOL cholesterol level has been related to
lipid-rich lesions rich in vessel walls and also to
other factors such as decreased vascular reactivity.
Animal studies and lesion pathology studies have
shown that, by lowering LOL cholesterol, endothe-
lial function was improved, atherosclerotic lesions-
especially the nonobstrucrive vulnerable plaques-
were stabilized, and inflammatory stimuli were re-
duced by removing lipoproteins from the circulation
and the arterial wall. As a result, prevention, slower
progression, and even reversal of atherosclerotic le-
sions have been observed.
Angiographic Trials
The first studies examining outcomes of lipid inter-
vention were angiographic trials. Large endpoint
trials were not performed initially due to their ex-
pense; intermediate studies were needed to show
the benefits of lipid-lowering treatment. Evaluation
of angiographic outcomes also established how le-
sions were altered, the ultimate goal of which was
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the examination of clinical benefits over long-term
trials. Many trials and a variety of treatments have
been performed. In all of them, lowering LOL cho-
lesterol resulted in a reduction of cardiovascular
events (Table 2). For the National Heart, Lung and
Blood Institute (NHLBI) Type II study [4], a treat-
ment combining diet and resin resulted in a lower-
ing of LOL cholesterol and an increase in triglyc-
erides. A reduction in both LOL and high density
lipoprotein (HOL) cholesterol was observed in the
Lifestyle Heart Study (LHS) [5] with a treatment
including a low-fat diet, relaxation, and exercise.
The Program on the Surgical Control of Hyperc-
holesterolemia (POSCH) Study [6] compared diet
and surgery and resulted in a marked lowering of
LOL cholesterol, an increase in triglycerides, and a
reduction in coronary events and total mortality.
These various treatments consistently reduced LOL
cholesterol levels (they had variable effects on other
lipoproteins) and consistently decreased coronary
events. Angiographic changes provided informa-
tion on how underlying lesions were altered and
how the lesion size was related to cardiovascular
events. Although event reduction was not statisti-
cally significant for each study, a consistent and
remarkable reduction in cardiovascular events by
lowering LDL cholesterol has been observed since
1972 across a number of angiographic trials.
Statin Trials
The prime objective of statin trials was to lower
LOL cholesterol and to assess the effects on total
mortality or coronary heart disease (Table 2).
These studies provided crucial information to the
health economist from which actual financial ben-
efit could be calculated.
The Scandinavian Simvastatin Survival Study (4S)
[71 was a secondary prevention trial designed to in-
vestigate the effect of long-term therapy with sirn-
Table 2 Coronary events and lipid level outcomes in selected lipid intervention trials
LDL HDL Coronary
cholesterol cholesterol Triglycerides events
Trial Treatment Years (%) (%) (%) (%)
NHLBI-CPPT Diet + resin 5 -II +5 +4.5 -19
LHS Low fat diet + relaxation + exercise I -37 8 -5 0
POSCH Diet + surgery :!: resin 9.7 -42 +3 +19.8 -35
4S Sirnvastatin 5 -35 +8 -10-12 -42
CARE Pravastatin 5 -28 +5 -14 -24
WOSCOPS Pravastatin 5 -26 +5 -12 -31
Post-CABG l.ovastatln + cholestyramine/resin 3 -38 0 0 -30
HDL, high density lipoprotein; LDL, low density lipoprotein.
NHLBI, National Heart, Lung and Blood Institute Study; LSH,Lifestyle Heart Study; POSCH, Program on the Surgical Control of Hypercholesterolemia; 4S, Scandi-
navian Simvastatin Survival Study; CARE, Cholesterol and Recurrent Events study; WOSCOPS, West of Scotland Coronary Prevention Study; Post-CABG, Post
Coronary Artery Bypass Graft Trial.
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vastatin in patients who had a previous myocardial
infarction (MI) or existing ischemic heart disease.
Middle-aged to elderly people with moderate to se-
vere hypercholesterolemia (total cholesterol 250-
280 mg/dl., LDL cholesterol 160-200 mgldL, and
triglycerides below 225 mgldL) were enrolled. This
trial was a titration towards goal study. Patients re-
ceived 20 mg simvastatin or placebo initially and
were titrated to higher doses (40 mg simvastatin)
for subjects with cholesterol levels remaining above
200 rng/dl.. The primary endpoint was total mor-
tality; the secondary endpoint was major coronary
events; and tertiary endpoints included types of
coronary events, angioplasty, and bypass surgery.
Treatment resulted in a 35% reduction in LDL cho-
lesterol, a small increase of about 8% in HDL cho-
lesterol, and a moderate 10-12% reduction in trig-
Iycerides. Although a univariant relationship was
observed between baseline triglycerides and cardio-
vascular events in the placebo group, this relation-
ship disappeared with a lowering of LDL choles-
terollevels by simvastatin. Coronary mortality was
reduced by 42%, and a reduction of 30% in all-
cause mortality was observed. Significant reduc-
tions were obtained for all other cardiovascular
endpoints. Major coronary events and total mortal-
ity decreased consistently for patients above and be-
low 60 years of age. Reduction of major coronary
events was consistent between men and women.
Reduction of total mortality was significant in men,
whereas the number of deaths among women was
too low to reach statistical significance. For dia-
betic patients, lowering of LDL cholesterol levels
without modifying their diabetic treatment resulted
in substantial reduction of coronary heart disease,
death, MI, and total mortality, as well as an insignif-
icant reduction in coronary heart mortality. Lower-
ing LDL cholesterol levels was beneficial for patients
in the lowest, middle, and highest quartiles of LDL
cholesterol. The same trend was observed irrespec-
tive of HDL cholesterol. A decrease in LDL choles-
terollevels for subjects with low HDL cholesterol re-
sulted in a reduction in coronary events without
significant impact on their HDL cholesterol. A re-
duction in cerebrovascular disease was also ob-
served, as reported in the Cholesterol and Recurrent
Events (CARE) [8] and POSCH [6] studies.
The CARE study [8] investigated the effect of
lipid-lowering therapy in men and women with
previous MI. The population enrolled was 60 years
old on average, with 15% women, a significant
number of patients with hypertension and diabetes,
and about 20'.10 smokers. Patients received a fixed
dose (40 mg) of pravastatin or placebo. At baseline,
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cholesterol was below 240 mg/dL, LDL cholesterol
was between 115 and 174 rng/dl., and triglyceride
levels reached a maximum of 350 mg/dl., A goal of
mean cholesterol level of 200 mg/dL was achieved
for the treatment group, with mean LDL choles-
terol levels reduced to 140 mg/dL (28% reduction).
HDL cholesterol level was lower than average at
entry. As expected, this population had a 5% in-
crease in HDL cholesterol and a 14% reduction in
mean triglyceride level. Lowering LDL cholesterol
in these patients with mild to moderate hypercho-
lesterolemia resulted in a significant reduction of
coronary heart disease, death, or nonfatal MI, as
well as a consistent decrease in every cardiovascular
endpoint, including unstable angina and bypass
surgery. In addition, a 30% reduction in stroke was
obtained. Lowering LDL cholesterol was beneficial
for men and women, subjects above and below 60
years of age, patients with ejection fraction rates
both less than and above 40%, nonsmokers or
smokers, diabetics, and subjects with hypertension
or who already had coronary bypass surgery. Pa-
tients with MI and who were mildly hypercholes-
terolemic also benefited from this cholesterol-low-
ering therapy. Despite these additional risk factors,
reduction in cardiovascular events was observed for
every risk category as a result of lowering LDL cho-
lesterol. This study shed new light on cholesterol-
lowering therapy by demonstrating a significant
reduction in coronary events in patients with cho-
lesterollevels below 240 mg/dL, which represents a
large majority of survivors of MI.
The West of Scotland Coronary Prevention Study
(WOSCOPS) [91 was a primary prevention, double-
blind, placebo-controlled and community-based
study. Male subjects, aged 45-64 with high LDL
cholesterol levels (155-232 mg/dL), were random-
ized to receive a fixed dose of pravastatin (40 mg/
dL) or placebo with an average follow-up of 5 years.
Endpoints were nonfatal MI and all the usual car-
diovascular endpoints. The average total choles-
terol at entry was 272 mg/dL, LDL cholesterol was
about 200 mg/dL, and HDL cholesterol and tri-
glyceride levels were a little higher than in the stud-
ies described above. A 26% reduction in LDL cho-
lesterol was achieved, in addition to a 12%
reduction in triglycerides and a slight increase in
HDL cholesterol. In terms of coronary events, very
consistent findings were observed for all cardiovas-
cular endpoints with a 31% reduction in nonfatal
MI and death. Benefits were also observed for sub-
groups of patients with other risk factor such as
age, smoking, or prevascular disease. Treatment
resulted in reduction of cardiovascular events for
118
patients with cholesterol levels below and above
189 mgldL. Benefits were slightly higher for pa-
tients with lower LOL cholesterol levels.
The Post Coronary Artery Bypass Graft Trial
(Post-CABG) [lOJ was a treat-to-goal postoperative
angiographic trial designed to assess the effects of
aggressive reduction of LDL cholesterol levels. Pa-
tients (1350) who had bypass surgery in the previous
1-11 years with moderately elevated LOL choles-
terol (130-175 mg/dL) were randomized to either
lovastatin at 80 mg per day and cholestyrarnine, or
lovastatin at 2.5 mg per day and resin. An aggres-
sive target of 85 mgldL of LDL cholesterol was set,
as was a moderate target of 130-140 mg/dL. Quan-
titative coronary angiography was used to deter-
mine treatment effect on lesions. The aggressive tar-
get of 85 mg/dL was not achieved since the mean on
treatment LDL was 96 mgldL. This demonstrated
the difficulty of reducing LDL cholesterol to very
low levels. For the moderate group, LDL cholesterol
levels were reduced from 150-160 mg/dL to 134-
136 mg/dL. Treatment resulted in no difference in
Hfrl. cholesterol levels between groups. The aggres-
sive treatment group consistently showed a 28-50%
reduction in new lesions. Progression of disease was
also limited and a significant reduction in the revas-
cularization rate was reported. A 30% reduction in
cardiovascular events was obtained for patients
(second bypasses and angioplasties), which is con-
sistent with all the previous angiographic trials.
For all the statin trials, whether in primary or
secondary prevention, lowering of LOL choles-
terol in various patient groups resulted in a 25-
35% reduction in coronary mortality and morbid-
ity. Benefits were observed rapidly, after 12-18
months of therapy.
LDL Cholesterol as a Causative Factor
for CAD
LDL reduction is thus the treatment of choice in
prevention of heart disease because clinical benefit
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occurs irrespective of the mechanism by which LOL
is decreased. Whether the lipid-lowering therapy in-
cludes diet, surgery, a resin or a statin, it is associ-
ated with improvement in exercise electrocardio-
grams, angiography, and angina, and the benefits
are dose dependent. A reduction of cardiovascular
events was observed with any mechanism that
caused the lowering of LDL cholesterol level, ir-
respective of changes in HOL cholesterol or trig-
lyceride levels. Reduction of LDL cholesterol was
beneficial even in patients where treatment raised
triglycerides or in patients where no change or a re-
duction in their HDL cholesterol levels occurred.
Table 3 summarizes the extent of the relation-
ship between CAD and lipid levels. Every criterion
defined previously is satisfied for LDL cholesterol,
demonstrating causality between LOL cholesterol
and CAD. HOI, cholesterol levels satisfy almost
all of the criteria, whereas triglyceride levels sat-
isfy only a few. These findings illustrate that thor-
ough evaluation of any risk factor should be per-
formed to show that all the criteria are satisfied
before causality is implied.
Conclusions
For almost 30 years, consistent clinical findings
have contributed to the validation of the early hy-
pothesis regarding the relationship between LDL
cholesterol and cardiovascular events. Over the
years, all the criteria required to assess the causal-
ity of LOL cholesterol on CAO have been satisfied
progressively and systematically. Consistent inter-
ventional benefit demonstrates that reduction of
LDL cholesterol is the method of choice in preven-
tion of heart disease. Further research in this field
should be performed to show how to apply these
conclusions to public health policy or standard
medical practice.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
Table 3 The strength of relationship between lipidsllipoproteins and IHO
Criteria
Strength
Independence
Biological consistency
Observational consistency
Measurement validity
Temporal relationship
Interventional benefit
LDL cholesterol
***
***
***
***
**
***
***
HDL cholesterol
**
***
**
**
**
***
T riglycerides
*
*
*
***
*
HDL, highdensity lipoprotein; IHD, ischemicheart disease;LDL low density lipoprotein; *, criterion satisfied.
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